Overview

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo in participants aged 6 to 70 years for the treatment of dyskinesia due to cerebral palsy (DCP).
Phase:
Phase 3
Details
Lead Sponsor:
Neurocrine Biosciences